Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.44, moving -1.99% from the previous trading session. This change lagged the S&P 500's 0.21% loss on the day. Meanwhile, the ...

This research advances hybrid soft-rigid robot simulations, achieving up to 1000 times faster computations through analytical derivatives in the GVS framework.

Those that solve artificially simplified problems where quantum advantage is meaningless. Those that provide no genuine quantum advantage when all costs are properly accounted for. This critique is ...

Overview Artificial intelligence seems to be transforming drug discovery in 2026, enabling faster molecule design, smarter clinical trials, and reduced R&D ...

Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will be featured in HighRes’ Lightning Talk at the NVIDIA GTC AI ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Recursion Pharmaceuticals developed a promising artificial intelligence (AI) platform for drug discovery and development. The company's clinical-stage pipeline is just the tip of the iceberg of its ...

MicroAlgo Inc. announced its research on the Quantum Information Recursive Optimization (QIRO) algorithm, which aims to address complex combinatorial optimization problems using quantum computing.

Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the following upcoming investor conferences: TD ...

The results of a recent survey released Tuesday showed President Trump's actions are likely to make it harder for biotech companies like Recursion to raise capital. The company reported ...

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. The move comes roughly ...